X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (26) 26
pulmonary hypertension (22) 22
female (18) 18
index medicus (18) 18
middle aged (17) 17
aged (15) 15
male (15) 15
arterial-hypertension (14) 14
hypertension, pulmonary - drug therapy (14) 14
adult (13) 13
respiratory system (12) 12
chronic disease (11) 11
hypertension, pulmonary - physiopathology (11) 11
epoprostenol - analogs & derivatives (10) 10
antihypertensive agents - administration & dosage (9) 9
cardiac & cardiovascular systems (9) 9
diagnosis (8) 8
epoprostenol - administration & dosage (8) 8
hypertension, pulmonary - etiology (8) 8
prognosis (8) 8
therapy (8) 8
treatment outcome (8) 8
treprostinil (8) 8
antihypertensive agents - therapeutic use (7) 7
follow-up studies (7) 7
hypertension, pulmonary - diagnosis (7) 7
pharmacology & pharmacy (7) 7
survival (7) 7
endarterectomy (6) 6
epoprostenol - therapeutic use (6) 6
pharmacokinetics (6) 6
prostacyclin analog (6) 6
antihypertensive agents - adverse effects (5) 5
care and treatment (5) 5
disease (5) 5
epoprostenol - adverse effects (5) 5
guidelines (5) 5
hypertension, pulmonary - mortality (5) 5
hypertension, pulmonary - surgery (5) 5
injections, subcutaneous (5) 5
kaplan-meier estimate (5) 5
peripheral vascular disease (5) 5
prostacyclin (5) 5
pulmonary arterial hypertension (5) 5
pulmonary embolism - complications (5) 5
severity of illness index (5) 5
subcutaneous treprostinil (5) 5
thromboembolism - complications (5) 5
administration, oral (4) 4
critical care medicine (4) 4
dose-response relationship, drug (4) 4
epoprostenol (4) 4
exercise test (4) 4
exercise tolerance - drug effects (4) 4
hypertension, pulmonary - blood (4) 4
iloprost (4) 4
intravenous epoprostenol (4) 4
long-term treatment (4) 4
patient outcomes (4) 4
prospective studies (4) 4
pulmonary arteries (4) 4
pulmonary embolism (4) 4
research (4) 4
retrospective studies (4) 4
risk factors (4) 4
thromboembolism (4) 4
thromboendarterectomy (4) 4
thrombosis (4) 4
abridged index medicus (3) 3
administration, inhalation (3) 3
aged, 80 and over (3) 3
antihypertensive agents - chemistry (3) 3
antihypertensive agents - pharmacology (3) 3
brain natriuretic peptide (3) 3
cardiology (3) 3
chronic thromboembolic pulmonary hypertension (3) 3
cohort studies (3) 3
congenital heart disease (3) 3
efficacy (3) 3
embolism (3) 3
endothelin receptor antagonists (3) 3
epoprostenol - chemistry (3) 3
epoprostenol - pharmacology (3) 3
expression (3) 3
heart-failure (3) 3
hemodynamics (3) 3
hypertension (3) 3
injections, intravenous (3) 3
internal medicine (3) 3
lesions (3) 3
lung transplantation (3) 3
medical prognosis (3) 3
medicine & public health (3) 3
mortality (3) 3
pharmacology/toxicology (3) 3
pharmacotherapy (3) 3
placebo-controlled trial (3) 3
pulmonary embolism - blood (3) 3
pulmonary embolism - surgery (3) 3
review (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Expert Review of Cardiovascular Therapy, ISSN 1477-9072, 12/2014, Volume 12, Issue 12, pp. 1391 - 1399
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 03/2007, Volume 5, Issue 3, pp. 483 - 489
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) results from non‐resolving pulmonary thromboemboli that are resistant to plasmatic... 
chronic thromboembolic pulmonary hypertension | prostacyclin analog | Chronic thromboembolic pulmonary hypertension | Prostacyclin analog | PHARMACOKINETICS | EPOPROSTENOL | ARTERIAL-HYPERTENSION | GUIDELINES | CONTINUOUS SUBCUTANEOUS INFUSION | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | LONG-TERM TREATMENT | BOSENTAN THERAPY | ILOPROST | Epoprostenol - blood | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Platelet Aggregation Inhibitors - blood | Time Factors | Pain - etiology | Hypertension, Pulmonary - drug therapy | Odds Ratio | Pulmonary Embolism - complications | Risk Assessment | Infusion Pumps | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - blood | Pulmonary Embolism - blood | Pulmonary Embolism - mortality | Vasodilator Agents - blood | Walking | Epoprostenol - analogs & derivatives | Chronic Disease | Hypertension, Pulmonary - etiology | Epoprostenol - administration & dosage | Vasodilator Agents - therapeutic use | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - blood | Case-Control Studies | Epoprostenol - therapeutic use | Pain - drug therapy | Platelet Aggregation Inhibitors - administration & dosage | Vascular Resistance - drug effects | Female | Thromboembolism - drug therapy | Platelet Aggregation Inhibitors - therapeutic use | Natriuretic Peptide, Brain - blood | Severity of Illness Index | Hypertension, Pulmonary - mortality | Cardiac Output - drug effects | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Thromboembolism - mortality | Thromboembolism - blood | Thromboembolism - complications | Pulmonary Embolism - drug therapy | Aged | Pain Measurement | Vasodilator Agents - administration & dosage
Journal Article
European Heart Journal, ISSN 0195-668X, 08/2017, Volume 38, Issue suppl_1
Journal Article
European Heart Journal, ISSN 0195-668X, 08/2013, Volume 34, Issue suppl 1, pp. P344 - P344
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2014, Volume 9, Issue 9, p. e106440
Journal Article
Journal Article
Journal of Heart and Lung Transplantation, ISSN 1053-2498, 2012, Volume 31, Issue 7, pp. 735 - 743
Journal Article